Literature DB >> 26397888

Current trends in the management of thyroid eye disease.

Rohini Rao1, Peter W MacIntosh, Michael K Yoon, Daniel R Lefebvre.   

Abstract

PURPOSE OF REVIEW: The present review summarizes the body of literature concerning the medical and surgical treatment of thyroid eye disease (TED) from 1 January 2014 through 30 March 2015. RECENT
FINDINGS: Corticosteroids continue to be the primary medical therapy for TED. Recent research has offered insight into potential differences between oral corticosteroid and intravenous corticosteroid treatment regimens in terms of efficacy and side-effect profiles. Steroid-sparing medications, for example, rituximab and others, are an area of active study. There has been renewed interest in the role of radiation therapy as a nonmedical treatment for TED with some promising data. The use of balanced orbital decompression techniques have become popular, although the data regarding postoperative diplopia are mixed, and 'fat decompression' offers an alternative or an augmentation to bony decompression. Stereotactic image guidance is a useful adjunct to orbital decompression surgery.
SUMMARY: TED continues to be a difficult condition for the patient to cope with and for the clinician to treat, and recent research builds on the present foundation of knowledge and treatments, but unfortunately does not offer paradigm-shifting information at the present time.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26397888     DOI: 10.1097/ICU.0000000000000203

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  9 in total

Review 1.  Orbital Decompression for Thyroid Eye Disease.

Authors:  Tara L Braun; Mohin A Bhadkamkar; Kevin T Jubbal; Adam C Weber; Douglas P Marx
Journal:  Semin Plast Surg       Date:  2017-02       Impact factor: 2.314

2.  Sphingosine-1-phosphate is involved in inflammatory reactions in patients with Graves' orbitopathy.

Authors:  Yuri Seo; Min Kyung Chae; Sol Ah Han; Eun Jig Lee; Joon H Lee; Jin Sook Yoon
Journal:  Inflamm Res       Date:  2017-03-31       Impact factor: 4.575

Review 3.  Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface.

Authors:  Priscila Novaes; Ana Beatriz Diniz Grisolia; Terry J Smith
Journal:  Clin Diabetes Endocrinol       Date:  2016-11-16

4.  A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy.

Authors:  Yang Wang; Shuo Zhang; Yidan Zhang; Xingtong Liu; Hao Gu; Sisi Zhong; Yazhuo Huang; Sijie Fang; Jing Sun; Huifang Zhou; Xianqun Fan
Journal:  BMC Endocr Disord       Date:  2018-02-20       Impact factor: 2.763

5.  Thyroid Eye Disease With Divergence Insufficiency Causing Recurrent Falls in an Elderly Patient.

Authors:  Wei Chen Lai; Nguyen S Nguyen; Azam Husain; Sachin D Rajpal; Miriam B Michael
Journal:  Cureus       Date:  2022-01-28

Review 6.  Multidisciplinary approach to orbital decompression. A review.

Authors:  Claudio Parrilla; Dario Antonio Mele; Silvia Gelli; Lorenzo Zelano; Francesco Bussu; Mario Rigante; Gustavo Savino; Emanuele Scarano
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-04       Impact factor: 2.124

Review 7.  Management of diplopia.

Authors:  Daniela Adriana Iliescu; Cristina Mihaela Timaru; Nicolae Alexe; Elena Gosav; Algerino De Simone; Mehdi Batras; Cornel Stefan
Journal:  Rom J Ophthalmol       Date:  2017 Jul-Sep

8.  Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.

Authors:  Mingkwan Lumyongsatien; Benjama Keeratidamkerngsakul; Kanokrat Pornpanich; Sumalee Vangveeravong; Preamjit Saonanon; Damrong Wiwatwongwana; Pornchai Mahaisavariya; Orapan Aryasit; Krit Pongpirul
Journal:  J Patient Rep Outcomes       Date:  2019-12-31

Review 9.  Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves' Ophthalmopathy: A Meta-Analysis.

Authors:  Jing Chen; Nuo Xu; Huilan Sun; Gang Chen
Journal:  J Ophthalmol       Date:  2021-07-12       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.